NPPB and hydrops fetalis: Thus, from the clinical perspective, another relevant issue concerning the NT-proBNP dosing in the diabetic population is related to its usefulness in identifying those patients who would benefit the most from this drug class before initiating treatment, also in the wake of data on biomarker-guided therapy that controversially and limited to the chronic HF setting was demonstrated to reduce CV outcomes, especially when pharmacological treatments with first-line drugs reached target doses [39, 40].